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1868Objectives: Surgical ventricular reconstruction has been believed to be beneficial for those with ischemic car-
diomyopathy. However, the effectiveness of surgical ventricular reconstruction was not proved by a large-scale
trial, and no report has clearly demonstrated the exact indications and limitations of surgical ventricular recon-
struction. The purpose of this study was to elucidate predictive factors of mortality after surgical ventricular
reconstruction and to develop a prognostic model by calculating risk scores.
Methods: The study subjects were 596 patients who underwent surgical ventricular reconstruction for chronic
ischemic heart failure in 11 Japanese cardiovascular hospitals between 2000 and 2010. Potential predictors of
postoperativemortality were assessed using the Cox proportional hazards model, and a risk scorewas calculated.
Results: Forty-one patients died before discharge, and 81 patients died during a mean follow-up time of 2.9
years. Four independent predictors of mortality were identified: age, Interagency Registry for Mechanically
Assisted Circulatory Support profile, left ventricular ejection fraction, and severity of mitral regurgitation.
Each variable was assigned a number of points proportional to its regression coefficient. A risk score was calcu-
lated using the point scores for each patient, and 3 risk groups were developed: a low-risk group (0-4 points), an
intermediate-risk group (5-6 points), and a high-risk group (7-12 points). Their 3-year survivals were 93%,
81%, and 44%, respectively (log-rank P<.001). Harrell’s C-index of the predictive model was 0.69.
Conclusions: A simple prognostic model was developed to predict mortality after surgical ventricular recon-
struction. It can be useful in clinical practice to select treatment options for ischemic heart failure. (J Thorac
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The Journal of Thoracic and Cardiovascular SurIndications for ischemic heart failure treatments vary de-
pending on the severity of the patient’s condition. Surgical
ventricular reconstruction (SVR) has been believed to be
beneficial for those with ischemic cardiomyopathy.1-3
However, the Surgical Treatment for Ischemic Heart
Failure (STICH) trial concluded that SVR plus coronary
artery bypass grafting (CABG) had no further beneficial
effect on survival compared with CABG alone.4 However,
the STICH results are controversial because this large-
scale trial enrolled patients with less severe disease than
in the previous studies supporting the effectiveness of
SVR.5 In contrast, implantable ventricular assist devices
(VADs) have become more common in the treatment of se-
vere heart failure and are filling a gap between medical
treatment and heart transplantation.6 However, VAD ther-
apy has inherent unresolved problems,7,8 such as
neurologic dysfunction, bleeding, device failure, pump
thrombosis, and lower cost-effectiveness, which may not
be associated with SVR. Therefore, SVR could be more
beneficial for appropriately selected patients compared
with CABG alone or VAD therapy. We hypothesized that
risk stratification for SVR could make it possible to identify
the responders to this procedure and therefore help
with appropriate patient selection, which in turn wouldgery c June 2014
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
INTERMACS ¼ Interagency Registry for
Mechanically Assisted Circulatory
Support
LV ¼ left ventricle
LVEF ¼ left ventricular ejection fraction
LVESVI ¼ left ventricular end-systolic
volume index
MR ¼ mitral regurgitation
NYHA ¼ New York Heart Association
STICH ¼ Surgical Treatment for Ischemic
Heart Failure
SVR ¼ surgical ventricular reconstruction
VAD ¼ ventricular assist device
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procedures for ischemic heart failure. Therefore, the pur-
pose of this study was to develop a practical prognostic
model to predict mortality after SVR for ischemic heart
failure by calculating a risk score using a multivariate
Cox proportional hazards model.
MATERIALS AND METHODS
Study Design
We conducted a retrospective multicenter study to investigate the out-
comes of SVR. Those who underwent SVR for ischemic heart failure
from 2000 to 2010 in 11 Japanese cardiovascular hospitals were enrolled
in this study. The indications for SVR were aneurysmal and akinetic left
ventricle (LV) in 194 patients (31%) and 412 patients (69%), respectively.
Participating hospitals were selected on the basis of the number of SVR
procedures performed annually. Principally, the hospitals that performed
5 or more SVR procedures annually were selected (n¼ 7). Although 4 hos-
pitals did not have 5 cases per year on average during the study period, they
were selected because they were leading cardiovascular centers in Japan
that also perform heart transplantation (n ¼ 2) or because of their recent
academic activities (n ¼ 2). The median number of SVR procedures in
each hospital during the study period was 52 (range, 17-166) cases. All
data were retrospectively collected from medical records and examination
reports. Mortality was detected on the basis of medical records or follow-up
inquiries to the attending cardiologists that were made in each hospital. The
study protocol was approved by the institutional review boards in all of the
participating hospitals.
Initially, 627 patients were enrolled in this study. Then those with acute
myocardial ischemia, no LVincision, and no follow-up data were excluded.
Finally, there were 596 study subjects. The LV sizes and functions were
measured using multiple modalities within 2 weeks before surgery. Postop-
erative imaging studies were repeated before discharge at 0.8 1.8 months
after surgery. Echocardiographywas performed for all the patients. LVend-
diastolic diameter, LV end-systolic diameter, and LV ejection fraction
(LVEF) were acquired by B-mode echocardiography. The severity of mitral
regurgitation (MR) was graded on the basis of color Doppler images as fol-
lows: 1þ ¼ mild, 2þ ¼ moderate, 3þ ¼ moderate-to-severe, and
4þ ¼ severe.9 The deceleration time was acquired from the transmitral
flow analysis. Systolic pulmonary artery pressure data were obtained
from the catheter data or estimated using echocardiographic data. The
LV end-diastolic volume index, LV end-systolic volume index (LVESVI),The Journal of Thoracic and Carand LVEF were collected from the results of left ventriculograms, quanti-
tative gated scintigrams, and magnetic resonance imaging in 288, 82, and
49 patients, respectively. For the patients with multimodality assessments,
the modality that was available both preoperatively and postoperatively
was selected to compare the values before and after surgery. Complete
imaging data sets of preoperative and postoperative values from the same
modality were acquired for LV diameters, LVEF, and LV volumes in 542
patients (91%), 515 patients (95%), and 299 patients (50%), respectively.
Statistical Analyses
Continuous variables were expressed as mean standard deviation, and
categoric variables were expressed as numbers and percentages. The
percentage was calculated exclusive of those with missing values. Preoper-
ative and postoperative data were compared using the Wilcoxon signed-
rank test. Intergroup comparisons for categoric data were conducted using
the chi-square test or Fisher exact test, if appropriate. Postoperative mortal-
ity was estimated using the Kaplan–Meier method, and differences in mor-
tality among groups were assessed by the log-rank test. Univariate and
multivariate Cox proportional hazards models were used to determine
the contributions of potential variables to the mortality. Variables for the
multivariate model were selected considering the proportion of patients
with missing data (<5%), the results of univariate analyses, their con-
founding, and the clinical importance. Selection of variables in the multi-
variate analysis was performed using the backward elimination method
(P< .10). Finally, to develop a practical prognostic score, we assigned
the independent predictors in the final Cox model weighted point scores
proportional to the b regression coefficient values (multiplied by a constant
and rounded to the nearest integer). A risk score was then calculated for
each patient, and the population was divided into 3 categories: patients at
low risk, patients at intermediate risk, and patients at high risk for postop-
erative mortality. The predictive accuracy of the scoring system was exam-
ined by calculating Harrell’s C-index.10 All analyses were performed using
IBM SPSS Statistics (v20; IBM Corp, Somers, NY).
RESULTS
Baseline Characteristics of Patients
Table 1 shows the patients’ baseline characteristics. Their
mean age was 63 10 (range, 29-87) years, and 372 (62%)
were male. In addition to the New York Heart Association
(NYHA) functional class, the Interagency Registry for Me-
chanically Assisted Circulatory Support (INTERMACS)
profile11 at the time of surgery was used for the assessment
of heart failure status. Those with NYHA functional class
I/II were categorized into INTERMACS profile level 7 or
more. Most of the patients (81%) presented with NYHA
functional class III/IV. Seventy-nine patients (13%)
required inotropic support preoperatively; of them, 21
patients (4%) had INTERMACS profile 1.
Surgical Procedures
Table 2 summarizes the operative procedures. Therewere
5 different SVR procedures performed: end ventricular cir-
cular patch plasty,12 partial left ventriculectomy,13 septal
anterior ventricular exclusion,14 overlapping left ventricu-
loplasty,15 and linear ventriculoplasty. Each procedure
was selected on the basis of the surgeons’ preferences in
each hospital. However, in common, an LV incision was
placed at the myocardial scar lesion that was determined ac-
cording to the findings of magnetic resonance imaging,diovascular Surgery c Volume 147, Number 6 1869
TABLE 1. Baseline characteristics of patients
N 596
Age, y (range) 63  10 (29-87)
Male sex, n (%) 372 (62%)
No. of diseased coronary arteries, n (%)
None 12 (2%)
1 112 (19%)
2 151 (25%)
3 321 (54%)
Coronary artery lesion, n (%)
Left main 76 (13%)
Anterior descending 545 (91%)
Circumflex 343 (58%)
Right 341 (57%)
LV shape, n (%)
Aneurysmal 184 (31%)
Akinetic 412 (69%)
Renal failure, n (%) 97 (16%)
Dialysis, n (%) 26 (4%)
Atrial fibrillation, n (%) 49 (8%)
Beta-blocker use, n (%) 224 (38%)
NYHA functional class, n (%)
I 22 (4%)
II 150 (25%)
III 267 (45%)
IV 156 (26%)
INTERMACS profile
Level 1 21 (3%)
Level 2 12 (2%)
Level 3 46 (8%)
Level 4 77 (13%)
Level 5-6 267 (45%)
Level 7 172 (29%)
Inotropic support, n (%) 79 (13%)
IABP, n (%) 73 (12%)
PCPS, n (%) 3 (0.5%)
IABP, Intra-aortic balloon pump; INTERMACS, Interagency Registry for Mechani-
cally Assisted Circulatory Support; LV, left ventricle; NYHA, New York Heart Asso-
ciation; PCPS, percutaneous cardiopulmonary support.
TABLE 2. Operative procedures
SVR procedures, n (%)
EVCPP 258 (43%)
PLV 14 (2%)
SAVE 184 (31%)
Overlapping 62 (11%)
Linear 78 (13%)
Patch/nonpatch 442 (74%)/154 (26%)
Mitral valve procedures, n (%) 259 (43%)
Plasty/replacement 251 (42%)/8 (1%)
Submitral procedures, n (%) 99 (17%)
Papillary muscle approximation 91 (15%)
Papillary muscle suspension 26 (4%)
CABG, n (%) 513 (86%)
No. of distal anastomoses 2.6  1.6
Tricuspid annuloplasty, n (%) 75 (13%)
Aortic valve replacement, n (%) 24 (4%)
Maze procedure, n (%) 22 (4%)
Surgical ablation for ventricular
tachyarrhythmia, n (%)
61 (10%)
ICD implant, n (%) 44 (7%)
Cardiopulmonary bypass time, min 181  70
Crossclamp time, min 101  54
CABG, Coronary artery bypass grafting; EVCPP, endoventricular circular patch
plasty; ICD, implantable cardiac defibrillator; PLV, partial left ventriculectomy;
SAVE, septal anterior ventricular exclusion; SVR, surgical ventricular reconstruction.
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Dechocardiography, or scintigraphy. A procedure using a
patch was performed in 442 patients (74%). Concomitant
mitral valve procedures were performed in 259 patients
(42%), most of whom underwent annuloplasty. CABG
was performed concomitantly in 513 patients (86%) who
had untreated coronary artery lesions.Cardiac Sizes and Functions
Table 3 summarizes perioperative cardiac sizes and func-
tions. LV sizes decreased and LVEF increased significantly
after surgery (P<.001 for each parameter). MR improved
postoperatively. Preoperatively, MR 3þ or more was
observed in 137 patients (24%), and 485 patients (93%)
had MR 1þ or less after surgery. In the analysis of the
299 patients with both preoperative and postoperative LV
volume data from the same modality, the mean LVESVI1870 The Journal of Thoracic and Cardiovascular Surreduction rates were 18%, 30%, and 37% for those with
baseline LVESVI 60 mL/m2 or less, 60 to 90 mL/m2, and
greater than 90 mL/m2, respectively; a reduction of 30%
or more was achieved for 44%, 55%, and 69% of them,
respectively. The LVEF increased significantly for each
group (LVESVI 60 mL/m2: 40% to 45%, P ¼ .001;
LVESVI 60-90 mL/m2: 30% to 38%, P ¼ .003; LVESVI
>90 mL/m2: 22% to 30%, P<.001).Postoperative Mortality
During the follow-up period of 2.9  2.5 years, 122 pa-
tients (21%) died. Among them, 12 patients (2%) and 41
patients (7%) died within 30 days after surgery and before
discharge from the hospital, respectively. Cardiac-related
death was observed in 60 patients (10%), 22 of whom
died before discharge. Readmission and reoperation were
required for 110 patients (19%) and 15 patients (3%),
respectively. Reoperation for MR was performed in 6 pa-
tients, including 2 replacements. Among them, 5 had previ-
ous mitral valve repair concomitant with SVR. Four
patients required an LV assist device, and 2 patients under-
went heart transplantation.Assessment of Potential Predictors of Mortality
Potential predictors of mortality were assessed using uni-
variate and multivariate Cox proportional hazards models
(Tables E1 and 4). Variables that were entered into the
multivariate Cox model were as follows: age, sex,gery c June 2014
TABLE 3. Perioperative cardiac sizes and functions
Preoperative Postoperative P value
LVDd, mm (range) 62  10 (37-90) 57  10 (33-82) <.001
LVDs, mm (range) 50  10 (13-83) 46  11 (20-74) <.001
LVEDVI, mL/m2
(range)*
144  51 (45-358) 103  36 (40-308) <.001
LVESVI, mL/m2
(range)*
107  47 (29-286) 70  33 (22-236) <.001
LVEF,% (range) 27  10 (5-78) 35  12 (4-65) <.001
DT, msec (range)* 190  73 (20-494) 183  61 (74-420) .15
SPAP, mm Hg
(range)*
36  17 (7-86) 34  18 (4-120) .08
MR grade 1.6  1.1 0.6  0.6 <.001
DT, Deceleration time; LVDd, left ventricular end-diastolic diameter; LVDs, left ven-
tricular end-systolic diameter, LVEDVI, left ventricular end-diastolic volume index;
LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume
index; MR, mitral regurgitation; SPAP, systolic pulmonary artery pressure. *Propor-
tion of those with missing values 30%.
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MR grade, SVR procedure, concomitant CABG, and
concomitant mitral valve procedures. Because data for
some variables were missing for some patients, the final
sample used in the multivariate analysis consisted of 570
patients, 113 of whom died.
Four independent predictors were identified in the final
multivariate Cox model: age, INTERMACS profile,
LVEF, and MR grade (Table 4). Harrell’s C-index of the
model was 0.690. Figure E1 shows Kaplan–Meier survival
curves for each predictor.TABLE 4. Multivariate Cox proportional hazards analysis and
scoring system
P value HR (95% CI)
b regression
coefficient Points
Age, y .001
<65 1 0
65 1.91 (1.29-2.85) 0.649 2
INTERMACS profile <.001
Level 1 4.54 (2.19-9.43) 1.513 4
Level 2 4.16 (1.79-9.67) 1.425 3
Level 3 2.71 (1.54-4.76) 0.995 2
Level 4 1.53 (0.90-2.60) 0.425 1
Level 5 1 0
LVEF,% .007
<20 3.63 (1.49-8.82) 1.289 3
20-40 2.26 (0.97-5.27) 0.816 2
40 1 0
MR <.001
1þ 1 0
2þ 2.09 (1.25-3.50) 0.738 2
3þ 2.08 (1.20-3.62) 0.734 2
4þ 5.09 (2.91-8.92) 1.628 4
CI, confidence interval; HR, hazard ratio; INTERMACS, Interagency Registry for
Mechanically Assisted Circulatory Support; LVEF, left ventricular ejection fraction;
MR, mitral regurgitation.
The Journal of Thoracic and CarDevelopment of Risk Categories for Postoperative
Mortality
Each independent predictor of mortality was assigned a
weighted score in points as shown in Table 4, and a risk
score was calculated for each patient by summing the scores
for the predictors. As a result, the risk score ranged from 0 to
12. Then 3 risk groups were developed according to the risk
scores: low risk (0-4 points), intermediate risk (5-6 points),
and high risk (7-12 points). The 30-day mortality rates were
0.3%, 0.7%, and 5% in the low-risk, intermediate-risk, and
high-risk groups, respectively (P ¼ .004). Hospital mortal-
ity percentages were 2%, 4%, and 22% for these groups,
respectively (P<.001).
Figure 1 shows Kaplan–Meier curves for all-cause sur-
vival and readmission-free survival. Both survivals were
significantly different among the 3 different risk groups
(P< .001 for each). The 3-year all-cause survivals were
93%, 81%, and 44% in the low-risk, intermediate-risk,
and high-risk groups, respectively. The 3-year
readmission-free survival rates were 78%, 65%, andFIGURE 1. Comparisons of Kaplan–Meier survival curves of each
risk group according to all-cause mortality (A) and readmission-free
survival (B).
diovascular Surgery c Volume 147, Number 6 1871
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groups, respectively.
NYHA functional classes at different time points were
compared among 3 risk groups (Figure E2). Those in the
high-risk group presented with a significantly worse
NYHA functional class than the others at every time point
(P<.001 for each). Approximately 90% of the low-risk pa-
tients and 80% of the intermediate-risk patients had NYHA
functional class of II or less at the latest follow-up.
DISCUSSION
In this study, we identified 4 independent predictors of
mortality after SVR for ischemic heart disease: age, IN-
TERMACS profile, LVEF, and MR grade. We developed
a prognostic model by calculating weighted risk scores as-
signed to those predictors. Then 3 risk categories were
developed to predict the prognosis according to the risk
scores.
Several treatment options can be selected for ischemic
heart failure depending on the patient’s condition: medica-
tion, revascularization, SVR, VAD, and heart transplanta-
tion. Because medication alone16 or CABG alone17 was
not associated with satisfactory results in those with severe
LV dilatation, acute reverse remodeling by SVR was ex-
pected to benefit such patients by reducing LV volume18
and restoring LV shape.19 Although a retrospective study
with a relatively small sample size showed favorable results
for SVR,20 a large-scale trial (STICH) found there was no
beneficial effect on survival in SVR plus CABG compared
with CABG alone.4 However, the validity of the STICH re-
sults is controversial.5,21 STICH seemed to enroll a CABG-
preferable population, considering the reported risk factors
related to CABG alone, such as an extensively dilated LV
and increased number of nonviable segments,22 as well as
severe LV systolic dysfunction.3 CABG alone or SVR
plus CABG may be appropriate for different populations
with a small overlap between them. Therefore, they cannot
be compared directly. Such a comparison, if the conditions
are matched as in the STICH trial, can exclude a number of
patients who are eligible for each procedure. Thus, it may
result in an inappropriate conclusion that does not reflect
the real world. Indeed, favorable results of SVR for those
excluded from STICH were reported.23,24
However, despite the criticism, that first large-scale trial
had enough power to make physicians and surgeons hesitate
to select SVR. Although the efficacy of SVR was denied for
patients without severe deterioration, the application of
SVR for more severe cases also has been considered nega-
tively. Instead, VAD therapy has become spotlighted in this
field. VAD has become the more common treatment for se-
vere heart failure, with progressive improvement of sur-
vival.6 It has advantages in terms of full functional
recovery of systemic circulation, although there are unre-
solved complications, such as stroke, hemorrhage, and1872 The Journal of Thoracic and Cardiovascular Surdevice failure.7 The cost also has been a problem in VAD
therapy.8 SVR does not increase the risk of such complica-
tions, although it can achieve partial functional recovery of
the heart because it uses the patient’s own diseased myocar-
dium. Therefore, it is natural that all patients cannot benefit
sufficiently from SVR, although it is more cost-effective if
performed for appropriately selected patients.25
Thus, a comprehensive approach for ischemic heart fail-
ure should be developed, including medication, catheter in-
terventions, CABG, SVR, VAD, and heart transplantation.
However, the conditions of the patients who are eligible
for them may be different. Thus, studies considering the
strata of different risk levels for each therapeutic option
may be required for more practical comparisons among
them and to find the optimal one for each patient. For this
purpose, risk stratification for SVR would be a meaningful
process to identify the responders to this procedure. We
therefore conducted this multicenter study to establish a
prognostic model to predict mortality after SVR. We
believe our results will contribute to the practical
decision-making process in the treatment of those with
ischemic heart failure.
INTERMACS Profile
An advanced NYHA functional class was reported to be
an independent predictor of adverse outcomes after
SVR.1,2,26 In our previous study, NYHA functional class
IV was also proved to be one of the strongest predictors
of mortality (Y.M and S.W., unpublished data, October
2010). In clinical practice, however, NYHA functional
class IV is not always associated with adverse outcomes.
Williams and colleauges27 reported that NYHA functional
class IV was not a significant predictor of mortality.
Inotropic dependence is a condition included in NYHA
functional class IVand may be a stronger predictor of mor-
tality. SVR for those with a maximum dose of inotropes for
cardiogenic shock was associated with high mortality.28 In
contrast, there was a report that concluded that inotrope use
was not a predictor of mortality after SVR for end-stage
ischemic cardiomyopathy.29 These various results indicate
that severe heart failure is a complicated and relatively
broad-spectrum condition.
The status of severe heart failure was recently catego-
rized in the INTERMACS profile for VAD therapy.11 It is
a detailed classification in terms of grading severe heart fail-
ure considering inotropic support, organ failure, and cardio-
genic shock. As far as we know, no study has evaluated the
outcomes of SVR using the INTERMACS profile. We
selected the INTERMACS profile as an integrated variable
including NYHA functional class, inotropic dependence,
hypotension, and renal failure. Moreover, analysis
including the INTERMACS profile can make it possible
to compare the results and indications for SVR with those
of VAD therapy. The indication for SVR should begery c June 2014
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treatment strategy for severe heart failure.
Left Ventricular Size
There is a contradiction about the indication for SVR in
that an extremely dilated LV is a risk for SVR,1 although a
dilated LVis an indication for the procedure.20 A recent sub-
analysis of the STICH trial concluded that SVR was worse
for those with a large LV.30 However, LV size is a variable
that has great potential for confounding (eg, the severity of
heart failure, MR grade, and LVEF), althoughmost previous
studies did not conduct a multivariate analysis of survival
time to assess the contribution of baseline LV size to postop-
erativemortality.1,2 In contrast, recent studies focused on the
postoperative LV volume (<60-70 mL/m2), with sufficient
volume reduction as an important predictor of adverse
outcomes.26,31 However, such studies can exclude those
whose condition is too severely deteriorated to undergo
postoperative LV assessment studies. Of course, in terms
of the quality of SVR, sufficient volume reduction and
postoperative LV volume may be important benchmarks.
If the concern is who is eligible for SVR, however, those
in a severely deteriorated condition should not be excluded
from the analysis. Therefore, we assessed only the
preoperative value in terms of LV size using a multivariate
Cox proportional hazards model with a relatively large
sample size. As a result, preoperative LV diameter itself
was not identified as a predictor of mortality after SVR. It
was also true that LV volume (LVESVI) did not predict
the mortality in the multivariate analysis including this
variable (n ¼ 406, data not shown). Therefore, our results
suggested that the patient’s condition (heart failure status)
and MR severity were more important predictors than LV
size. Even for patients with an extremely large LV, SVR
can be indicated if heart failure is well controlled and MR
is not severe.
Mitral Regurgitation and Mitral Procedures
In this study, preoperativeMR of 4þwas identified as the
strongest predictor of mortality, although all of the patients
with this condition underwentmitral valve surgery. This was
consistent with previous reports that preoperativeMR 3þ or
greater predicted mortality in those who underwent SVR
with mitral valve procedures.29,32 The STICH trial
recently suggested that additional mitral valve repair for
moderate to severe ischemic MR might improve survival
compared with CABG alone or medical treatment alone.33
In this study, however, a concomitant mitral valve procedure
was not identified as a predictor of survival. O’Neill and col-
leagues34 reported the outcomes of 220 consecutive patients
who underwent SVR. Mitral valve surgery was performed
for 49% of them but was not proved to affect survival. It
was difficult to assess the efficacy of a concomitant mitral
valve procedure because this was an observational studyThe Journal of Thoracic and Carand all of the patients with significant MR underwent the
mitral valve procedure. Further study will be required to
elucidate the efficacy of mitral procedures.
Surgical Ventricular Reconstruction Procedures
The appropriate selection of SVR procedures also may be
important. Suma and colleagues35 reported that site selec-
tion of the LV incision according to the location of the
scar lesion resulted in improvement of the survival after
SVR for nonischemic dilated cardiomyopathy. Various
SVR procedures were performed in our cohort, but the dif-
ferences of the procedures did not affect the outcomes.
Although the surgeons in each participating hospital
selected SVR procedures on the basis of their preferences,
they agreed in considering the regional myocardial viability
in selecting the location of the LV incision. Thus, the differ-
ence of the procedures (eg, patch use and shape) may not be
the predominant issue if the location of the LV incision is
appropriately selected. It is considered that 30% or more
reduction of LVESVI is required for an acceptable SVR
procedure.5 In our cohort, LVESVI reduction of 30% or
more was achieved in 44%, 55%, and 69% of those with
baseline LVESVI 60 mL/m2 or less, 60 to 90 mL/m2, and
greater than 90 mL/m2, respectively; these rates were
higher than those for the STICH trial (26%, 36%, and
45%, respectively).31 However, changes in LVEF were
comparable.
Study Limitations
First, the number of procedures performed in each
participating hospital was relatively small. However, the
results were similar among the participating hospitals
(log-rank P ¼ .11). Second, the relatively short length of
the follow-up period could reduce the statistical power of
our prognostic model. Third, some variables that may be
important (eg, diastolic function) could not be entered in
the multivariate analysis because of missing values. Fourth,
because only half of the patients had paired data for LV vol-
ume from the same modality, it could not be evaluated suf-
ficiently whether SVR in our cohort was performed
adequately. Fifth, we did not evaluate the generalizability
of our prognostic model using an external validation set.
Finally, this is a retrospective and noncomparative study.
Although we conducted risk prediction analysis regarding
SVR, this scoring system itself cannot indicate the benefit
of SVR compared with other treatments (eg, CABG alone,
medication, and VAD). Thus, a prospective study that com-
pares different treatment sets considering the risk stratifica-
tion for each treatment and examines our prognostic model
is required.
CONCLUSIONS
We developed a prognostic model to predict mortality
after SVR for those with ischemic heart failure. It can bediovascular Surgery c Volume 147, Number 6 1873
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in a comprehensive treatment strategy including medica-
tion, catheter interventions, CABG, SVR, VAD, and heart
transplantation. Moreover, risk stratification of SVR will
contribute to future studies comparing it with other treat-
ment options.
We used data from the Japanese Adult Cardiovascular Surgery
Database in selecting participating hospitals. The authors thank
Noboru Motomura, PhD, and Hiroaki Miyata, PhD, for planning
the study, and Koji Oba, PhD, for statistical help.
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FIGURE E1. Comparisons of Kaplan–Meier survival curves in terms of INTERMACS profiles (A), LVEF (B), MR (C), and age (D). INTERMACS,
Interagency Registry for Mechanically Assisted Circulatory Support; LV, left ventricle.
FIGURE E2. Comparisons of NYHA functional classes among risk
groups at different time points.
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TABLE E1. Assessment of potential predictors of mortality using
univariate Cox proportional hazards model
N P value
Hazard
ratio (95% CI)
Age, y .06
<65 306 1
65 290 1.40 (0.98-2.01)
Sex .65
Female 224 1
Male 372 0.92 (0.64-1.33)
NYHA functional class <.001
I 22 1
II 150 1.51 (0.36-6.44)
III 267 1.61 (0.39-6.66)
IV 156 4.46 (1.09-18.27)
Inotropic support <.001
No 513 1
Yes 79 3.79 (2.56-5.63)
INTERMACS profile <.001
Level 1 21 5.19 (2.48-10.89)
Level 2 12 7.74 (3.30-18.17)
Level 3 46 3.82 (2.09-6.99)
Level 4 77 1.99 (1.12-3.56)
Level 5-6 267 1.11 (0.67-1.84)
Level 7 172 1
LV shape* .07
Aneurysmal 184 0.68 (0.45-1.03)
Nonaneurysmal 379 1
LV end-diastolic diameter, mm <.001
55 142 1
55-60 118 1.56 (0.78-3.13)
60-70 206 2.28 (1.26-4.10)
>70 108 4.08 (2.25-7.40)
LVESVI, mL/min2,* .003
80 119 1
80-100 93 2.12 (0.88-5.12)
100-140 117 3.36 (1.53-7.40)
>140 89 4.13 (1.86-9.16)
LVEF,% <.001
20 135 4.60 (1.97-11.0)
20-40 354 2.66 (1.16-6.13)
>40 80 1
MR <.001
None 110 1
1þ 207 1.02 (0.51-2.04)
2þ 116 2.52 (1.30-4.92)
3þ 84 3.02 (1.51-6.04)
4þ 53 6.36 (3.13-12.91)
SVR procedure (patch use) .68
No patch 154 1
Patch 442 1.10 (0.72-1.68)
SVR procedure (type) .39
EVCPP 258 1
PLV 14 0.69 (0.10-5.00)
SAVE 184 1.32 (0.87-2.00)
Overlapping 62 1.61 (0.92-2.82)
Linear 78 0.96 (0.50-1.85)
(Continued)
TABLE E1. Continued
N P value
Hazard
ratio (95% CI)
CABG .001
Not performed 83 1
Performed 513 0.49 (0.32-0.76)
Mitral valve procedure <.001
Not performed 345 1
Performed 251 2.66 (1.85-3.83)
CABG, Coronary artery bypass grafting; CI, confidence interval; EVCPP, endoven-
tricular circular patch plasty; INTERMACS, Interagency Registry for Mechanically
Assisted Circulatory Support; LV, left ventricle; LVEF, left ventricular ejection frac-
tion; LVESVI, left ventricular end-systolic volume index; MR, mitral regurgitation;
NYHA, New York Heart Association; PLV, partial left ventriculectomy; SAVE, septal
anterior ventricular exclusion; SVR, surgical ventricular reconstruction. *Proportion
of those with missing values 5%.
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